Jeonnam National University and Nanobiosystem Challenge Commercialization of Wound Dressings

Jeonnam National University Campus View.

The core technology of Nanobiosystem Co., Ltd., a startup founded by a professor at Jeonnam National University, has been selected as a final recipient in the Ministry of SMEs and Startups' "SME Technology Innovation Development (R&D)" project, establishing a foundation for the commercialization of advanced regenerative nanostructured wound dressings, expanding their application from the laboratory to real-world medical settings.

Jeonnam National University announced on September 4 that the joint project, "Development and Industrialization of Next-Generation Nanopatterned Wound Dressings for Extensive Wound Treatment," led by Professor Lee Gunwoo's orthopedic research team at Jeonnam National University Hospital and Nanobiosystem Co., Ltd. (CEO Kim Jangho), has been selected for the Ministry's Technology Innovation Development (R&D) project, with a total funding of 640 million won.

In this research, Nanobiosystem Co., Ltd. will be responsible for the overall business, including product design, development, and regulatory approval, while the Jeonnam National University Hospital research team will conduct clinical trials to verify the product's efficacy and safety, aiming to accelerate commercialization.

The core of the research is the world's first implementation of an extracellular matrix (ECM) nanostructure in wound dressings. Through this, the team aims to develop an advanced regenerative medical device that promotes skin tissue regeneration, offering an innovative alternative for treating intractable skin conditions such as post-surgical skin damage and burns.

Nanobiosystem Co., Ltd. was founded by Professor Kim Jangho of Jeonnam National University and develops advanced regenerative medical devices and cosmetic products by integrating nanomaterials and stem cell technologies. CEO Kim is a leading authority in the field of tissue regeneration, with more than 170 SCIE-indexed papers and over 25 domestic and international patents. He has received several awards, including the Young Investigator Award from the World Tissue Engineering and Regenerative Medicine Society and the Samsung HumanTech Thesis Grand Prize.

Professor Lee Gunwoo of Jeonnam National University Hospital stated, "Based on my clinical experience in orthopedics, I will thoroughly verify patient safety and efficacy to develop a world-class wound dressing. I hope that the research outcomes will lead to tangible improvements in patients' quality of life."

CEO Kim Jangho said, "We will promptly commercialize products capable of dramatically treating patients with extensive wounds and lead the global advanced regenerative medicine market."

This content was produced with the assistance of AI translation services.